A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04219254)
A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Who can join: Review the eligibility criteria below.
Location: University of California Los Angeles — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- University of California Los Angeles — Los Angeles, California
- Sarah Cannon Research Institute — Denver, Colorado
- HealthPartners Institute - Regions Cancer Care Center, — Saint Paul, Minnesota
- Oklahoma University , Stephenson Cancer Center — Oklahoma City, Oklahoma
- NEXT Oncology — San Antonio, Texas
- LTD High Technology Hospital Med Center — Batumi,
- Israel-Georgian Medical Research Clinic Helsicore — Tbilisi,
- Jerarsi Clinic — Tbilisi,
- Medizinische Hochschule Hannover — Hanover,
- Nationales Centrum für Tumorerkrankungen — Heidelberg,
- Universität des Saarlandes — Homburg,
- Maria Skłodowska-Curie National Institute of Oncology — Gliwice,
- Medical University of Silesia — Katowice,
- Instytut Centrum Zdrowia Matki Polki — Lodz,
- Institutul Oncologic "Prof. Dr. Ion Chiricuta" — Cluj-Napoca,
- Centrul de Oncologie SF Nectarie SRL — Craiova,
- Hospital Universitari Dexeus — Barcelona,
- Hospital Universitari Vall D´Hebron — Barcelona,
- Institut Català d'Oncologia Hospital Duran i Reynals — Barcelona,
- Hospital Puerta de Hierro — Majadahonda,
- Hm Ciocc Málaga — Málaga,
- Clinica Universidad de Navarra — Pamplona,
- Hospital Virgen de la Macarena — Seville,
- Sahlgrenska University Hospital — Gothenburg,
- Lund University Hospital — Lund,
📞 Contact the Study Coordinator
Phone: +46735504521
Email: philipp.zimmermann@bioinvent.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.